You are here: Industry Insights > COVID-19

News List

Deadly 'Black Fungus' Disease Spotted in Americans With COVID-19 Drugs
December 17, 2021
It's a phenomenon first identified in India earlier this year: Patients who have or are recovering from COVID-19 who then contract a sometimes deadly fungal infection known as mucormycosis -- also known as "black fungus."
EMA CHMP recommends J&J’s Covid-19 booster for adults Pharmaceutical-Technology
December 17, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion on the usage of Johnson & Johnson’s (J&J) Covid-19 vaccine as a booster shot for adults aged 18 years and above.
Kineret receives positive CHMP opinion for treatment of COVID-19 pneumonia pharmatimes
December 17, 2021
The European Medicines Agency has recommended approval for use of Kineret in COVID-19 to the European Commission, which will issue a final decision.
Vaccines still provide ‘significant protection’ against severe COVID-19 PharmaTimes
December 16, 2021
Omicron has been the latest variant to test the effectiveness of COVID-19 vaccines.
Needle free COVID-19 vaccine trialled in UK PharmaTimes
December 16, 2021
The DIOSvax technology produced by the University of Southampton aims to predict how the virus could mutate.
AAP Issues Guidance for Children's Emotional Needs During COVID-19 Drugs
December 16, 2021
In guidance issued by the American Academy of Pediatrics, recommendations are presented to help pediatricians support the emotional and behavioral needs of children, teenagers, and families during the COVID-19 pandemic.
COVID-19 Severity Does Not Differ for Patients With Skin Conditions Drugs
December 16, 2021
For patients with psoriasis, vitiligo, atopic dermatitis (AD), and chronic urticaria (CU), COVID-19 severity does not differ, but treatment of COVID-19 may affect the course of skin disease...
Samsung Biologics and AstraZeneca expand manufacturing partnership to include COVID-19 and cancer therapies CPhIonline
December 16, 2021
CDMO currently manufacturing LAAB combination treatment and will start on cancer immunotherapy product from next year.
Atea to study AT-527 as monotherapy and in combination for Covid-19 Pharmaceutical-Technology
December 16, 2021
Atea Pharmaceuticals has announced an update to its strategy to use AT-527 as a single agent and in combination against the SARS-CoV-2 virus and the new variants.
Covid-19: Pfizer’s antiviral Paxlovid effective against severe disease and Omicron variant Pharmaceutical-Technology
December 16, 2021
Pfizer has announced that its investigational Covid-19 antiviral, Paxlovid, offers high protection against severe disease from coronavirus and is effective against the new variant Omicron.